ABBONANTE, VITTORIO
 Distribuzione geografica
Continente #
NA - Nord America 894
EU - Europa 801
AS - Asia 461
AF - Africa 4
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 2.164
Nazione #
US - Stati Uniti d'America 883
CN - Cina 426
IE - Irlanda 341
IT - Italia 129
DE - Germania 108
FI - Finlandia 82
SE - Svezia 67
GB - Regno Unito 41
SG - Singapore 18
UA - Ucraina 17
CA - Canada 10
CZ - Repubblica Ceca 8
JP - Giappone 7
MU - Mauritius 4
IR - Iran 3
IN - India 2
PL - Polonia 2
RO - Romania 2
TR - Turchia 2
AU - Australia 1
BD - Bangladesh 1
BE - Belgio 1
BR - Brasile 1
CL - Cile 1
ES - Italia 1
EU - Europa 1
FR - Francia 1
HK - Hong Kong 1
NL - Olanda 1
PA - Panama 1
SA - Arabia Saudita 1
Totale 2.164
Città #
Dublin 341
Chandler 254
Nanjing 115
Ashburn 108
Beijing 78
Pavia 62
Helsinki 58
Jacksonville 55
Boardman 45
Nanchang 40
Shenyang 40
Lawrence 38
Princeton 38
Medford 37
Changsha 27
Wilmington 26
Tianjin 25
Hebei 24
New York 22
Jiaxing 21
Shanghai 21
Hangzhou 15
Ann Arbor 11
Washington 11
Augusta 10
Singapore 9
Toronto 9
Woodbridge 9
Tokyo 7
Brno 6
Gallarate 6
Hanover 6
Dallas 5
Leawood 5
Milan 5
San Francisco 5
Norwalk 4
Seattle 4
Ardabil 3
Fairfield 3
Fiesole 3
Jinan 3
Los Angeles 3
Chongqing 2
Falkenstein 2
Ningbo 2
Olomouc 2
Piscataway 2
Polska 2
Redwood City 2
Verrua Po 2
Amsterdam 1
Bovisio Masciago 1
Brussels 1
Buccinasco 1
Casorate Sempione 1
Castiglione Olona 1
Central 1
Chengdu 1
Chicago 1
Dhaka 1
Elk Grove Village 1
Esslingen am Neckar 1
Fuzhou 1
Geislingen an der Steige 1
Guangzhou 1
Melbourne 1
Modena 1
Monza 1
Munich 1
Naples 1
Orange 1
Petriolo 1
Phoenix 1
Piacenza 1
Pune 1
Qingdao 1
Reston 1
Riyadh 1
Rockville 1
Rozzano 1
Sassari 1
Selargius 1
São Paulo 1
Taizhou 1
Torre del Greco 1
Turin 1
Vanzaghello 1
Vigevano 1
Walnut 1
Würzburg 1
Zhengzhou 1
Totale 1.674
Nome #
Biocompatibility of functionalized boron phosphate (BPO4) nanoparticles for boron neutron capture therapy (BNCT) application 97
Adhesion to different collagens modulates megakaryocyte development 93
Altered fibronectin expression and deposition by myeloproliferative neoplasm-derived mesenchymal stromal cells 82
Folic acid-conjugated 4-amino-phenylboronate, a boron-containing compound designed for boron neutron capture therapy, is an unexpected agonist for human neutrophils and platelets 81
Definition of the Native and Denatured Type II Collagen Binding Site for Fibronectin Using a Recombinant Collagen System 74
Discoidin Domain Receptor 1 is a novel modulator of megakaryocyte-collagen interactions 74
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 72
The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control 67
Effect of Interferon-γ on the Basal and the TNF α-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement or the BRAF V600e Mutation 66
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 65
Thrombopoietin/TGF-β1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis 65
Thrombopoietin/TGF-β1 loop regulates megakaryocyte extracellular matrix component synthesis 64
The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells 63
Alternatively spliced fibronectin extra domain A is required for hemangiogenic recovery upon bone marrow chemotherapy 62
Phenotypical, Functional and Genetic Characterization of Mesenchymal Stem Cells Derived from the Spleen of Patients with Myelofibrosis. 61
The AMPK-activator AICAR in thyroid cancer: effects on CXCL8 secretion and on CXCL8-induced neoplastic cell migration 60
JAK2 exon 14 Skipping in Patients with Primary Myelofibrosis (PMF). 59
Abnormal regulation of intracellular Ca2+ in human megakaryocytes contributes to the pathophysiology of CALR-mutant myeloproliferative neoplasms. 58
Hyaluronan based hydrogels provide an improved model to study megakaryocyte-matrix interactions 58
Upregulation of lysyl oxidase and adhesion to collagen of human megakaryocytes and platelets in primary myelofibrosis 57
Extracellular matrix nano-mechanics determines megakaryocyte function 57
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 55
Gel-free sample preparation for the nanoscale LC-MS/MS analysis and identification of low-nanogram protein samples 54
EDA fibronectin–TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis 54
A newly identified platelet and megakaryocyte lysyl oxidase adhesion to collagen axis in human primary myelofibrosis 52
DDR1 activation determines megakaryocyte migration on type I collagen. 51
EDA Fibronectin-TLR4 Axis Sustains Megakaryocyte Expansion and Inflammation during Bone Marrow Fibrosis Progression. 49
Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity 49
Recombinant collagen engineered to bind to discoidin domain receptor functions as a receptor inhibitor 48
Human megakaryocytes confer tissue factor to a subset of shed platelets to stimulate thrombin generation 47
A new path to platelet production through matrix sensing 46
Three-dimensional tissue models for studying ex vivo megakaryocytopoiesis and platelet production 44
iPSC diversity: A key for better use and improved targeting 42
Bone marrow microenvironment of MPN cells 39
Mechanisms of platelet release: in vivo studies and in vitro modeling 38
Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver 36
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 35
Ablation of Collagen VI leads to the release of platelets with altered function 32
Increased B4GALT1 expression is associated with platelet surface galactosylation and thrombopoietin plasma levels in MPNs 25
Lack of COL6/collagen VI causes megakaryocyte dysfunction by impairing autophagy and inducing apoptosis 16
Novel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis 12
null 7
Totale 2.266
Categoria #
all - tutte 9.225
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.225


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020122 0 0 0 5 0 4 18 4 18 30 39 4
2020/2021147 15 3 0 38 0 7 3 19 42 12 8 0
2021/2022262 4 0 5 49 3 1 2 8 11 45 28 106
2022/2023727 81 75 7 54 55 54 2 34 335 4 13 13
2023/2024357 40 57 12 9 31 137 3 35 2 7 10 14
2024/202574 24 50 0 0 0 0 0 0 0 0 0 0
Totale 2.266